Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Celltrion Inc

Mr. Hyong-Gi  Kim

CEO & Internal Director

Mr. Woo-Sung  Kee

Jin-seok  Seo

Co-CEO & Inside Co-Chairman of the Board

Mr. Stephen  Yeum

Founder

Mr. Min-Cheol  Shin

Director of Finance

Mr. Ji-Hoon  Choi

Director of Legal Affairs

Celltrion Inc (068270) Stock Analysis, Discussion Forum and Financial Metrics - KRX Exchange

068270's latest dividend is 500 KRW on December 27, 2023

068270 Stock Discussion Forum and Message Board

News for KRX: 068270